WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006020706) TIE COMPLEX BINDING PROTEINS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/020706    International Application No.:    PCT/US2005/028413
Publication Date: 23.02.2006 International Filing Date: 09.08.2005
IPC:
C07K 16/28 (2006.01), A61K 39/395 (2006.01), C07H 21/04 (2006.01)
Applicants: DYAX CORP. [US/US]; 300 Technology Square, 8th Floor, Cambridge, MA 02139 (US) (For All Designated States Except US).
WOOD, Clive, R. [US/US]; (US) (For US Only).
DRANSFIELD, Daniel, T. [US/US]; (US) (For US Only).
PIETERS, Henk [NL/NL]; (NL) (For US Only).
HOET, Rene [NL/NL]; (NL) (For US Only).
HUFTON, Simon, E. [GB/GB]; (GB) (For US Only)
Inventors: WOOD, Clive, R.; (US).
DRANSFIELD, Daniel, T.; (US).
PIETERS, Henk; (NL).
HOET, Rene; (NL).
HUFTON, Simon, E.; (GB)
Agent: MYERS, Louis; Fish & Richardson P.C., P.O.Box 1022, Minneapolis, MN 55440-1022 (US)
Priority Data:
10/916,840 12.08.2004 US
PCT/US2004/026116 12.08.2004 US
11/049,536 02.02.2005 US
Title (EN) TIE COMPLEX BINDING PROTEINS
(FR) PROTEINES DE LIAISON AU COMPLEXE TIE
Abstract: front page image
(EN)Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders.
(FR)Tie1 et Tie2 sont des protéines tyrosine kinases réceptrices comportant un domaine transmembranaire. Tie1 et Tie2 sont présents sur des cellules endothéliales. La présente invention a trait à des agents, tels que des anticorps, de liaison à Tie1, Tie2, et à l'angiopoiétine, comprenant ceux qui sont inhibiteurs de l'activité de cellules endothéliales et de l'angiogenèse. Les agents peuvent être utilisés pour le traitement de troubles associés à l'angiogenèse.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)